Skip to content

Brimonidine with Local Anesthetic Cream for Safer and More Comfortable Mesotherapy

Topical Brimonidine as an Effective and Safe Adjuvant to Local Anesthetics for Mesotherapy: A Randomized Split-Face Cross-Over Trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600118854
Enrollment
Unknown
Registered
2026-02-11
Start date
2026-02-01
Completion date
Unknown
Last updated
2026-02-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None

Interventions

Control group (lidocaine-prilocaine group):Lidocaine–prilocaine cream
Intervention group(brimonidine combined with lidocaine-prilocaine):Lidocaine–prilocaine cream plus brimonidine

Sponsors

The Third Affiliated Hospital of Guangzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1.Male or female subjects of yellow race, aged between 18 and 60 years (inclusive); 2.Participants with self-requested improvement of skin tone or texture; 3.Presence of bilaterally symmetrical facial treatment areas; 4.Ability to understand and comply with the study requirements and to complete follow-up visits; 5.Consent to randomization for placement into the microneedling therapy group or the microinjection therapy group; 6.Willing and able to provide written informed consent.

Exclusion criteria

Exclusion criteria: 1. Do not agree to sign the informed consent form; 2. Individuals preparing for pregnancy, pregnant, or breastfeeding; 3. Individuals with liver or kidney dysfunction; 4. Individuals who are highly allergic to amide-type local anesthetics or any components of compound lidocaine cream; 5. Individuals allergic to any components of bromonidine tartrate or bromonidine tartrate eye drops; 6. Patients being treated with monoamine oxidase inhibitors and patients using antidepressants that affect norepinephrine transmission; 7. Patients with congenital or idiopathic methemoglobinemia; 8. Patients with syndromes related to vascular dysfunction, cerebral or coronary artery insufficiency, Raynaud's phenomenon, orthostatic hypotension, thromboangiitis obliterans, or severe cardiovascular malformations.

Design outcomes

Primary

MeasureTime frame
Pain score (VAS, Visual Analog Scale);

Secondary

MeasureTime frame
Patient satisfaction;Erythema score;Efficacy assessment;Edema score;

Countries

China

Contacts

Public ContactLi Xueqing

The Third Affiliated Hospital of Guangzhou Medical University

2023683196@gzhmu.edu.cn+86 20 8129 2652

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 19, 2026